CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Creative Enzymes Unveils Custom Blends Product Line for Bioprocessing Solutions

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

908 Devices Launches MAVERICK for Real-Time In-Line Monitoring of Multiple Bioprocess Parameters

MAVERICK is a Raman-based PAT solution that requires no complex modeling. It is an optical in-line analyzer that provides real-time monitoring and control of glucose, lactate, and total biomass in mammalian cell cultures, in addition to rich process fingerprint data to support large-scale efforts in predictive bioprocess modeling. MAVERICK is also the first turn-key device to utilize Raman spectroscopy for bioprocess control, with no modeling and development required. With its in-line optical sampling probe, biopharmaceutical scientists and engineers can quickly develop their cell culture media and design feeding and control strategies.

Health Plan of San Joaquin Selects ZeOmega to Elevate Complete Care Management

Health Plan of San Joaquin (HPSJ) just announced they selected ZeOmega’s care management solution to support the complex health needs of 450,000+ Medi-Cal members and promote equitable care statewide. HPSJ will use ZeOmega’s platform to consolidate and analyze members’ health data to produce insights informing care needs. The partnership will empower HPSJ to support members’ physical, mental, and behavioral health needs and align with CalAIM’s whole-person approach to healthcare.

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

Bora merges with Sunway Biotech to launch global Nutraceuticals offering

Kalderos names veteran healthcare leader Angie Franks as new CEO

Kalderos names veteran healthcare leader Angie Franks as new CEO

ResultsCX Achieves a 'Major Contender' Status in Everest Group's Customer Experience Management Services PEAK Matrix® Assessment 2023, Americas

Assessment is the Latest Industry Recognition of the Value ResultsCX Delivers Through its End-to-End CX Solutions

Integrated DNA Technologies and Aldevron® Activate Strategic Partnership to Deliver Key CRISPR Components to Cell and Gene Therapy Developers

Integrated DNA Technologies will sell Aldevron cGMP-manufactured CRISPR nucleases to enable customers to rapidly transition from discovery to clinic.

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth

Mural Health Raises $8M Led by Bessemer Venture Partners to Accelerate Growth Funding enables Mural Health to expand its Mural Link platform to modernize the clinical trial participant experience

AVIA Launches Innovative AI Labs, AI Co-pilot for Digital Health Transformation

AVIA's newest AI-focused initiative aims to share practical application of AI to better inform - and transform - the healthcare industry

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

This presentation will offer practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.

Mount Nittany Medical Center Increases Accuracy and Efficiency of Vancomycin Dosing Using InsightRX Model-Informed Precision Dosing Platform

Mount Nittany Medical Center Increases Accuracy and Efficiency of Vancomycin Dosing Using InsightRX Model-Informed Precision Dosing Platform

Kalderos Adds Powerful Features to Commercial Drug Discount Monitoring Solution

Kalderos Adds Powerful Features to Commercial Drug Discount Monitoring Solution - Drug Discount Management Leader Delivers New Tools to Tackle Billions in Overpaid Commercial Rebates

Watson-Marlow Fluid Technology Solutions to Showcase Fluid Path Product Range at ISPE Boston

Visit stand W113 to meet WMFTS engineers and discuss single use fluid path processes at ISPE Annual Product Show